menu
    • menu
    [{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"venBio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Spray dried dispersion","sponsorNew":"Ventyx Biosciences \/ venBio","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ venBio"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Surveyor Capital"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Viela Bio"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Redmile Group","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VTX958","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VTX958","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VTX3232","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VTX958","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VTX3232","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"VTX3232","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Ventyx Biosciences

    Menu

    Ventyx Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $27.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

                            Details : In connection with the equity investment, the Company has agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights.

                            Brand Name : VTX3232

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $27.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Initiates Dosing in Phase 2a Trial of VTX3232 for Early Parkinson’s

                            Details : VTX3232 is NLRP3 inflammasome inhibitor, small molecule drug candidate, being evaluated for patients with parkinson's disease.

                            Brand Name : VTX3232

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 06, 2024

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX958

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Results from Phase 2 Trial of VTX958 in Crohn’s Disease

                            Details : VTX002 is a potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Patients with moderately to severely active crohn’s disease.

                            Brand Name : VTX958

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : VTX958

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX3232,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Reveals Positive Data for NLRP3 Inhibitor VTX3232 in Obesity Treatment

                            Details : VTX3232 is an oral CNS-penetrant NLRP3 inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of patients with obesity.

                            Brand Name : VTX3232

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2024

                            Lead Product(s) : VTX3232,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Reports NLRP3 Inhibitor Data and Pipeline Updates at Investor Event

                            Details : VTX3232 is NLRP3 inflammasome inhibitor, small molecule drug candidate. It is currently being evaluated for the treatment of patients with parkinson's disease.

                            Brand Name : VTX3232

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : VTX3232

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

                            Details : Ventyx aims to use proceeds from the proposed private placement to fund the clinical development of VTX002, currently in Phase II trials for ulcerative colitis.

                            Brand Name : VTX002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX958

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaq...

                            Details : VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Patients with Moderate to Severe Plaque Psoriasis.

                            Brand Name : VTX958

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2023

                            Lead Product(s) : VTX958

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Se...

                            Details : VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Ulcerative Colitis.

                            Brand Name : VTX002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 09, 2023

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and...

                            Details : VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Ulcerative Colitis. VTX958, an oral, selective, allosteric TYK2 inhibitor used for treatment of Plaque...

                            Brand Name : VTX002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2023

                            Lead Product(s) : VTX002

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX958

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treat...

                            Details : The wide therapeutic window of VTX958 observed in our Phase 1 trial will allow us to explore a broad range of doses in Phase 2 trials, including doses designed to achieve biologic-like IC90 coverage of TYK2-mediated cytokines, such as IL-23.

                            Brand Name : VTX958

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : VTX958

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth